Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization Learn more



Our Mission


Everything we do starts with our Mission: to enable our customers to make the world healthier, cleaner, and safer. The nature of our business is to enable growth and innovation within the global scientific community and to help researchers, organizations, and companies solve some of the world’s most pressing issues. We do that by providing cutting-edge technologies and services that are the result of our significant investment in research and development. We believe creating a better tomorrow starts with the action we take today, and we continually strive toward improvement and excellence for the benefit of our customers, our colleagues, and the world. 

Innovating for a better tomorrow

Great strides have been made over the last two decades in cancer research thanks in part to technology such as next-generation sequencing (NGS). The amount of genomic data generated as a result of faster and more robust NGS platforms has helped lead to a better understanding of cancer, and this information is advancing the development of therapies that are helping to prolong the lives of many cancer survivors.

 

Despite these advances, the vast majority of patients are not yet benefiting from them because the technology that can help match them more quickly to potentially more effective therapies is generally not yet available in community hospitals, where most patients are diagnosed and treated.

 

Thermo Fisher took a major step toward providing increased access to genomic testing through the introduction of the Ion Torrent Genexus System in 2019. The NGS platform is the first system of its kind that is able to generate a comprehensive genomic profile in a single day. It is also designed with an automated, simple-to-use workflow that virtually any properly-certified hospital lab can adopt, and can return a comprehensive genomic report using minimal amounts of sample. 

 

Spend on research & development




Healthier

Quotation marks
"Today we have taken an important next step toward redefining the way cancer patients can be tested in the future. We envision a time when patients at local hospitals will have access to timely, comprehensive genomic test results that can guide better targeted therapy selection and improve health outcomes as the standard of care.”

Mark Stevenson
Chief Operating Officer

Innovating for a better tomorrow

Great strides have been made over the last two decades in cancer research thanks in part to technology such as next-generation sequencing (NGS). The amount of genomic data generated as a result of faster and more robust NGS platforms has helped lead to a better understanding of cancer, and this information is advancing the development of therapies that are helping to prolong the lives of many cancer survivors. Despite these advances, the vast majority of patients are not yet benefiting from them because the technology that can help match them more quickly to potentially more effective therapies is generally not yet available in community hospitals, where most patients are diagnosed and treated. Thermo Fisher took a major step toward providing increased access to genomic testing through the introduction of the Ion Torrent Genexus System in 2019. The NGS platform is the first system of its kind that is able to generate a comprehensive genomic profile in a single day. It is also designed with an automated, simple-to-use workflow that virtually any properly-certified hospital lab can adopt, and can return a comprehensive genomic report using minimal amounts of sample.


Cleaner

In 2018, the U.S. Army started doing testing on Thermo Fisher Scientific™ Parallel Twin-Screw Extruder, using it to produce 3D filament from post-consumer polyethylene terephthalate (PET) found in plastic water bottles – one of the most common waste products left on the battlefield. This filament will be used to 3D print spare parts as needed to increase wartime readiness and reduce dependency on the logistical supply chain. The process will result in less plastic waste and will lower cost and shorten the lead time to get replacement parts to troops in remote areas.

 


Quotation marks
“With our enemies forced to innovate rapidly to survive, it’s becoming increasingly important for the U.S. military to improve its own agility and flexibility. With additive manufacturing, parts could be produced where they are needed, when they’re needed.”

Nicole Zander
U.S. Army Research Lab

Safer

There is a growing need for monitoring radiation exposure driven by increased global awareness of the link between levels of exposure and cancer. Daily monitoring for radiation exposure is a standard regulatory procedure in medical and imaging facilities, dental offices, veterinary clinics, nuclear power plants, laboratories, and other industries that work with sources of radiation. To safeguard employees from the dangers of radiation exposure and ensure a secure work environment, these facility operators turn to Thermo Fisher Scientific.

 

After more than 30 years of working with customers on dosimetry equipment selection and deployment, Thermo Fisher has launched a dosimetry monitoring service that streamlines the radiation safety process for customers through a single provider, providing support to smaller offices and providers who may have difficulty managing dosimetry programs on their own. Our service delivers personal radiation measurement badges – dosimeters – which provide readings about the dose of ionizing radiation an individual receives. The badge data is then read to produce recurrent dose reports, creating a harmonized approach to internal dosimetry processing.